Peak concentration of gemcitabine at fixed-dose-rate and its hematological toxicity profile.
- Author:
Lin-run WANG
1
;
Guo-bing ZHANG
;
Ming-zhu HUANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antimetabolites, Antineoplastic; administration & dosage; adverse effects; pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols; adverse effects; pharmacokinetics; therapeutic use; Carboplatin; adverse effects; blood; pharmacokinetics; Carcinoma, Non-Small-Cell Lung; drug therapy; metabolism; Chromatography, High Pressure Liquid; Deoxycytidine; adverse effects; analogs & derivatives; blood; pharmacokinetics; Female; Humans; Infusions, Intravenous; Lung Neoplasms; drug therapy; metabolism; Male; Metabolic Clearance Rate; Middle Aged; Neutropenia; chemically induced; Thrombocytopenia; chemically induced
- From: Journal of Zhejiang University. Medical sciences 2007;36(4):391-395
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the relationship between peak concentration (Cmax) of gemcitabine at fixed-dose-rate and its hematological toxicity profile in patients with advanced non-small-cell lung cancer (NSCLC).
METHODSTwenty-one patients received gemcitabine at a fixed dose rate (1200 mg/m2 over 120 min) with carboplatin. Plasma concentrations of gemcitabine were measured by ion-pair reversed-phase high-performance liquid chromatography.
RESULTSThe mean value of Cmax in 21 eligible patients was(4.95+/-2.42) microg *ml(-1). The main hematological toxicity was grade III-IV thrombocytopenia and neutropenia. The mean percentages of reduction of WBC, NEC, PLTC and Hb of 21 patients were (38.3+/-38.1)%, (31.3+/-73.6)%, (31.8+/-53.5)% and (12.0+/-12.2)%, respectively. The C(max)of gemcitabine and the percentage of reduction in WBC showed a significant correlation (r2=0.4575, P<0.05). A significant correlation (r2=0.5671, P<0.05) was also observed between the percentage of reduction of PLTC and Cmaxof gemcitabine.
CONCLUSIONThe results of relationship between Cmax and toxicity profile suggest that gemcitabine administration should be individualized in order to decrease the occurrence of ADR.
